A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Essential hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 07 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Status changed from recruiting to completed.
- 28 Jul 2016 Planned patient no changed from 494 to 363.